1-methylcyclopropyl 9-(5-fluoro-6-(2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenylamino)pyrimidin-4-yloxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate

ID: ALA4172962

Chembl Id: CHEMBL4172962

PubChem CID: 68036951

Max Phase: Preclinical

Molecular Formula: C24H25F2N7O4

Molecular Weight: 513.51

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC1(OC(=O)N2CC3COCC(C2)C3Oc2ncnc(Nc3ccc(-n4cncn4)cc3F)c2F)CC1

Standard InChI:  InChI=1S/C24H25F2N7O4/c1-24(4-5-24)37-23(34)32-7-14-9-35-10-15(8-32)20(14)36-22-19(26)21(28-12-29-22)31-18-3-2-16(6-17(18)25)33-13-27-11-30-33/h2-3,6,11-15,20H,4-5,7-10H2,1H3,(H,28,29,31)

Standard InChI Key:  AFFLSSIXCBCWOQ-UHFFFAOYSA-N

Associated Targets(Human)

GPR119 Tclin Glucose-dependent insulinotropic receptor (4762 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Gpr119 Glucose-dependent insulinotropic receptor (559 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 513.51Molecular Weight (Monoisotopic): 513.1936AlogP: 3.09#Rotatable Bonds: 6
Polar Surface Area: 116.52Molecular Species: NEUTRALHBA: 10HBD: 1
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.54CX Basic pKa: 2.60CX LogP: 2.59CX LogD: 2.59
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.53Np Likeness Score: -0.99

References

1. Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O'Neill K, Tang H, Greenlee WJ..  (2018)  Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.,  (5): [PMID:29795759] [10.1021/acsmedchemlett.8b00073]

Source